Page 9 - CUA Adv Prostate Ca Drug Access List-MAR-2022

BRITISH COLUMBIA Link to Patient Assistance Programs HOME

Funding:
Medications for active cancer treatment are funded by BC Cancer for all BC Medical Services Plan patients (including First Nations Health Authority clients). These medications are
supplied at no charge to registered BC cancer patients at BC Cancer Centres and Clinics.
Patients may also have private drug plans that cover some or all of medication costs.

Formularies:
BC Pharmacare Formulary - https://pharmacareformularysearch.gov.bc.ca/
BC Cancer Benefit Drug List - http://www.bccancer.bc.ca/systemic-therapy-site/Documents/Policy%20and%20Forms/Benefit%20Drug%20List.pdf

DRUG Strength,
(Brand Name) Indication Route DIN Provincial Funding Eligibility Criteria References
Manufacturer
A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
1
Restricted funding* Protocol
2
Eligibility (Abiraterone + Prednisone) : UGUPABI
1
• Patients with mCRPC who are chemotherapy-naïve OR have received prior chemotherapy 2. [2-22]
BC Cancer
containing docetaxel
o ECOG PS 0-2 Benefit Drug
List [3-22]
o Life expectancy > 3 months
• Patients can receive abiraterone (UGUPENZ) OR enzalutamide (UGUPABI, but not
sequential use of these agents
Not
mCRPC Tablet 1
specified Exclusions :
• Active or symptomatic viral hepatitis or chronic liver disease
• History of adrenal dysfunction
• Clinically significant heart disease (LVEF < 50% at baseline)
• Previously received abiraterone, enzalutamide or apalutamide for mCSPC
• Previously received apalutamide, enzalutamide or darolutamide in nmCRPC
Abiraterone
(Zytiga) Caution :
1
Janssen • Bilirubin > 1.5 x ULN, ALT > 2.5 x ULN
Generic • Uncontrolled hypertension

1
A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
Restricted funding* Protocol
2
Eligibility (Abiraterone + Prednisone) : UGUMCSPAB
1
I [2-22]
• Patients with mCSPC who are either chemotherapy-naïve OR received prior
chemotherapy containing docetaxel 2. BC Cancer
o No prior ADT or ADT for < 6 months for mCSPC Benefit Drug
List [3-22]
Not • Should have ECOG PS 0-2
mCSPC Tablet
specified • Should have serum potassium > 3.5 mmol/L

Note:
• Patients treated with abiraterone for mCSPC and develop mCRPC are eligible to receive
enzalutamide (but not abiraterone)

Caution :
1
• Uncontrolled hypertension (systolic blood pressure > 160 mmHg or diastolic > 95 mmHg)

Page 5 | © Canadian Urological Association
v.01-MAR-2022